|

Aldesleukin Clinical Trials

20 actively recruiting trials across 6 locations

▲ +1 trial since May 2026

Also known as: 125-L-Serine-2-133-interleukin 2, IL-2, Interleukin 2, IL-2, IL2, Interleukin-2, Proleukin +3 more

Pipeline

Early 1: 1Phase 1: 4Phase 2: 6Phase 3: 1Phase 1/2: 7

Top Sponsors

  • National Cancer Institute (NCI)8
  • Christian Hinrichs3
  • University of Southern California1
  • Tongji Hospital1
  • St. Anna Kinderkrebsforschung1

Indications

Bethesda, Maryland9 trials

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

National Institutes of Health Clinical Center

Phase 2
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

National Institutes of Health Clinical Center

Phase 1/2
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center

Phase 1/2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center

Phase 2
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

National Institutes of Health Clinical Center

Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

National Institutes of Health Clinical Center

Phase 2
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

National Institutes of Health Clinical Center

Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center

Phase 2

Other5 trials

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
Phase 1/2
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/2
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Phase 3
Immunotherapy for the Treatment of Advanced Solid Tumor
Phase 1/2
Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

New Brunswick, New Jersey2 trials

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Rutgers Cancer Institute

Phase 1/2
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Rutgers Cancer Institute of New Jersey

Phase 1

Los Angeles, California1 trial

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

USC / Norris Comprehensive Cancer Center

Phase 1

Miami, Florida1 trial

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Sylvester Comprehensive Cancer Center - Miami

Phase 1/2

Atlanta, Georgia1 trial

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Emory University/Winship Cancer Institute

Early 1

Rochester, Minnesota1 trial

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Mayo Clinic in Rochester

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.